Curated News
By: NewsRamp Editorial Staff
May 11, 2026

HeartBeam Launches Pilot Study for On-Demand 12-Lead ECG Patch

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • HeartBeam's pilot study targets the $2B patch monitoring market, potentially giving early investors a strategic edge in cardiac ischemia detection.
  • HeartBeam's patch synthesizes 12-lead ECG from three non-coplanar directions, compared against standard ECGs in a 50-patient pilot study.
  • HeartBeam's cable-free device enables ambulatory ischemia detection, allowing patients to receive timely cardiac care outside hospitals.
  • HeartBeam’s 3D ECG technology, already FDA-cleared for arrhythmia, now aims to detect ischemia with a patch worn after exercise.

Impact - Why it Matters

This news matters because HeartBeam's pilot study could validate a breakthrough in ambulatory cardiac monitoring. If successful, the patch may enable early detection of coronary artery disease outside hospital settings, potentially saving lives by catching ischemia earlier. For investors, it signals progress toward a major market opportunity in the $2 billion patch-based monitoring space. Patients could benefit from more accessible and convenient cardiac diagnostics, reducing the need for repeated hospital visits.

Summary

HeartBeam (NASDAQ: BEAT) has announced the initiation of a pilot study evaluating its investigational on-demand 12-lead ECG patch in approximately 50 patients with suspected coronary artery disease at two hospitals in Belgrade, Serbia. The study will compare synthesized 12-lead ECG readings generated by the company’s patch immediately following exercise stress testing against standard 12-lead ECGs. This trial supports HeartBeam’s regulatory strategy for a device designed to expand ambulatory cardiac monitoring beyond rhythm assessment into ischemia detection within an established approximately $2 billion patch-based monitoring market. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement, underscoring its innovative approach to cardiac care.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Launches Pilot Study for On-Demand 12-Lead ECG Patch

blockchain registration record for this content.